Therapeutic agents—I

Details Therapeutic agents—I Therapeutic agents—I

2002-12-09

2008-11-11

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

Reexamination Certificate

active

07449492

ABSTRACT:
The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects. The present invention further contemplates a method for the prophylaxis and/or treatment in mammalian, animal or avian subjects of infection or potential infection by pathogenic entities by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family of plants or their botanical or horticultural derivatives or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or in the form of a chemical fraction, sub-fraction, preparation or extract of the plant.

REFERENCES:
patent: 4418064 (1983-11-01), Powell et al.
patent: 4560774 (1985-12-01), Pettit et al.
patent: 4716179 (1987-12-01), Hecker et al.
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5317009 (1994-05-01), Lee-Huang et al.
patent: 5643948 (1997-07-01), Driedger et al.
patent: 5716968 (1998-02-01), Driedger et al.
patent: 5750568 (1998-05-01), Driedger et al.
patent: 5886017 (1999-03-01), Driedger et al.
patent: 5886019 (1999-03-01), Driedger et al.
patent: 5891870 (1999-04-01), Driedger et al.
patent: 5891906 (1999-04-01), Driedger et al.
patent: 5932613 (1999-08-01), Jiang et al.
patent: 5962498 (1999-10-01), Driedger et al.
patent: 6268395 (2001-07-01), Hattori
patent: 6432452 (2002-08-01), Aylward
patent: 6593371 (2003-07-01), Staggs
patent: 6787161 (2004-09-01), Aylward et al.
patent: 6844013 (2005-01-01), Aylward et al.
patent: 2003/0171334 (2003-09-01), Aylward et al.
patent: 2003/0171337 (2003-09-01), Aylward et al.
patent: 2003/0195168 (2003-10-01), Aylward et al.
patent: 2005/0003031 (2005-01-01), Aylward et al.
patent: 2005/0209192 (2005-09-01), Aylward et al.
patent: 1077129 (1993-10-01), None
patent: 1105246 (1995-09-01), None
patent: 1112011 (1995-11-01), None
patent: 1131037 (1996-09-01), None
patent: 29 02 506 (1979-01-01), None
patent: 0 455 271 (1991-11-01), None
patent: 0 310 622 (1992-04-01), None
patent: 0 330 094 (1999-08-01), None
patent: 208790 (1993-01-01), None
patent: 8-13571 (1996-01-01), None
patent: 8-176002 (1996-07-01), None
patent: 8-245505 (1996-09-01), None
patent: WO 87/07599 (1987-12-01), None
patent: WO 97/15575 (1997-05-01), None
patent: 99/08994 (1999-02-01), None
Drug Actions, Basic Principles and Therapeutic Aspects, published 1995 by CRC Press (FL), pp. 515-580.
De Clercq, “In Search of a Selective Antiviral Chemotherapy”, Clinical Microbiolgy Reviews, vol. 10, No. 4, Oct. 1997, pp. 674-693.
The Merck Manual of Diagnosis and Therapy, published 1982 by Merck Sharp & Dohme Research Laboratories, pp. 200-203.
English Language Translation of Tamas et al., Hungarian Patent Publication No. 208 790 B, published Jan. 28, 1994, pp. 1-14.
The Merck Manual of Diagnosis and Therapy, 14thedition, published in 1982 by Merck Sharp & Dohme Research Laboroatories, pp. 2046-2049.
Hohmann, et al. “Jatrophane diterpenoids fromEuphorbia peplus”, Phytochemistry51: 672-677.
Hohmann, et al. “Diterpenoids fromEuphorbia peplus”, Planta Med.66: 291-294 (2000).
Krauter, et al., “Structure/activity relationships of polyfunctional diterpenes of tigliane type”, Eur. J. Biochem, 242, pp. 417-427 (1996).
El-Merzabani, et al., Planta Med. 1979 vol. 36, pp. 150-155.
M. Belkin,et al. “Tumor-Damaging Capacity of Plant Materials. I. Plants Used as Cathartics”, National Cancer Institute: Apr. 13, 1952, pp. 139-149.
D. Weedon, et al. “Home Treatment of Basil Cell Carcinoma”, Med. J. Aust., Jun. 1, 1976, p. 928.
Zayed, et al. J. Cancer Res. Clin. Oncol. 1998. vol. 124, pp. 301-308.
Benjamini, et al. Immunology—A Short Course. 1988, Publ: Allan R. Liss, Inc. NY. pp. 15-18.
Abo, K.A. Fitoterapia, 1988. vol. LIX, No. 3, pp. 244-246.
Alastair Aitken, et al., “The Activation of Protein Kinase C by Daphnane, Ingenane and Tigliane Diterpenoid Esters”,Botanical Journal of the Linnean Society, vol. 94 pp. 247-263 (1987).
Sahar El-Mekkawy, et al., “Anti-HIV-1 Phorbol Esters from the Seed ofCroton Tiglium”, Phytochemistry, vol. 53 pp. 457-464, (2000).
U.S. Appl. No. 11/324,587, filed Jan. 3, 2006, Aylward et al.
F. J. Evans et al, “Pro-Inflammatory, Tumor-Promoting and Anti-Tumor Diterpenes of the Plant Families Euphoribiaceae and Thymelaeaceae” Department of Pharmacognosy, The School of Pharmacy, University of London, References, vol. 44, pp. 90-99, date not provided.
Tian-Shung Wu et al., “Antitumor Agents, 1191Kansuiphorins A and B, Two Novel Antileukemic Diterpene Esters FromEuphorbia Kansui”, Journal of Natural Products, May-Jun. 1991, vol. 54, No. 3, pp. 823-829.
Salah M.A.D. Zayed et al., “Dietary cancer risk from conditional cancerogens in produce of livestock fed on species of spruge (Euphorbiaceae) I. Skin irritant and tumor promoters of the ingenane diterpene ester type”, Cancer Res. Clin. Oncol, 1998, 124: pp. 131-140.
B D Curti “Physical barriers to drug delivery in tumors”, Critical Reviews in Oncology/Hematology, 1993; 14: pp. 29-39.
G B Dermer, “Another Anniversary for the War on Cancer”, Bio/Technology, Mar. 1994, vol. 12, p. 320.
T. Gura, “Systems for Identifying New Drugs are Often Faulty”, Science, Nov. 1997, vol. 278, pp. 1041-1042.
R.I. Freshney, “Culture of Animal Cells, A Manual of Basic Technique”, Department of Clinical Oncology, Cancer Research Campaign Laboratories, University Glasgow, no date.
L H Hartwell, et al. Integrating Genetic Approaches in the Discovery of Anticancer Drugs, Science, vol. 278, Nov. 7, 1997, pp. 1064-1068.
R K Jain, “Barriers to Drug Delivery in Solid Tumors”, Scientific American, Jul. 1994, pp. 58-65.
Extract from Endocrinology, Proceedings of the American Association for Cancer Research, vol. 36, Mar. 1995, p. 256.
Office Action dated Jan. 12, 2007 in co-pending U.S. Appl. No. 10/315,319.
Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4thEdition (1995): 1314-1323; 1330-1335 and 1590-1603.
Uemura D. et al., “New Diterpene, 13-Oxyingenol, Derivative Isolated FromEuphorbia KansuiLiou”,Tetrahedron Letters29:2529-2532 (1974).
Kupchan S.M. et al., “Antileukemic Principles Isolated From Euphorbiaceae Plants”,Science191:571-572 (1975).
Kupchan S.M. et al., “Gnidimacrin and Gnidimacrin 20-Palmitate, Novel Macrocyclic Antileukemic Diterpenoid Esters FromGnidia Subcordata”, Communications to the Editor5719-5720 (1976).
Evans F.J. et al., The Tigliane, Daphnane And Ingenane Diterpenes, Their Chemistry, Distribution And Biological Activities, A Review,Lloydia41(3):193-233 (1978).
Hecker E., “Structure-Activity Relationships In Diterpene Esters Irritant And Cocarcinogenic To Mouse Skin”,Carcinogenesis2:11-48 (1978).
Seip E.H. et al., “Skin Irritant Ingenol Esters FromEuphorbia Esula”, Planta Medica46:215-218 (1982).
Nishizuka Y., “The Role Of Protein Kinase C In Cell Surface Signal Transduction And Tumour Promotion”,Nature308:693-698 (1984).
Schmidt R.J., “The Ingenane Polyol Esters”,Naturally Occurring Phorbol Esters, Boca Rato

Affiliated with

Also associated with

Rating

Therapeutic agents—I does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents—I, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents—I will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4036490